Tirzepatide vs Retatrutide
Bottom line
Tirzepatide is an FDA-approved dual GIP/GLP-1 agonist with a mature Phase 3 evidence base and a known safety profile — the practical choice today. Retatrutide is an investigational triple GIP/GLP-1/glucagon agonist posting the largest weight-loss figures yet reported (~28–30% in Phase 3), but it is not approved, its long-term safety is unestablished, and any product sold now is unverified gray-market material. One is a prescribable medicine; the other is a promising candidate still in trials.
At a glance
| Tirzepatide | Retatrutide | |
|---|---|---|
| Class | Dual GIP/GLP-1 receptor agonist | Triple GIP/GLP-1/glucagon (GCGR) receptor agonist |
| Primary use | Type 2 diabetes; obesity; obstructive sleep apnea | Investigational — obesity, T2D, MASLD, OA-related outcomes (trials) |
| Evidence level | Approved — SURPASS, SURMOUNT Phase 3 programs | Clinical — Phase 2 complete; Phase 3 TRIUMPH reporting (investigational) |
| Typical weight loss | ~15–20.9% over 72 wks (SURMOUNT-1) | ~24.2% at 48 wks (Phase 2, 12 mg); ~28.3% at 80 wks / ~30.3% at 104 wks (TRIUMPH-1) |
| Half-life | ~5 days | ~6 days |
| Route | Subcutaneous | Subcutaneous |
| Legal / FDA status | FDA-approved — Mounjaro (T2D, 2022), Zepbound (obesity 2023; OSA 2024) | Not approved — investigational; Phase 3 TRIUMPH program; regulatory submission anticipated late 2026/early 2027 |
Key Differences
- Mechanism — two targets vs three. Tirzepatide activates GIP and GLP-1. Retatrutide adds a third receptor, glucagon (GCGR), which is thought to raise energy expenditure and promote hepatic fat oxidation on top of the appetite and glycemic effects of the incretin arms — a mechanism absent from dual agonists.
- Weight loss magnitude. Retatrutide’s trial figures are the highest reported for an obesity drug: ~24.2% at 48 weeks (Phase 2, 12 mg) and ~28.3% at 80 weeks with ~30.3% in a 104-week extension (TRIUMPH-1, 12 mg) — approaching bariatric-surgery territory. Tirzepatide reaches ~15–20.9% in SURMOUNT-1. Note these come from separate trials, not a head-to-head, so cross-trial comparisons are imperfect.
- Evidence maturity — the decisive gap. Tirzepatide is approved with large completed Phase 3 programs and post-marketing experience. Retatrutide is investigational: Phase 2 is complete and Phase 3 TRIUMPH topline results are positive, but long-term safety and final regulatory status are not yet established.
- Glucagon trade-off. The glucagon arm that may boost fat loss can theoretically oppose glycemic lowering and is associated with a dose-dependent heart-rate increase under monitoring in trials. Tirzepatide’s profile is better characterized.
- Availability and sourcing. Tirzepatide is a prescription medicine with quality-assured branded product (Mounjaro/Zepbound). Retatrutide has no approved product — anything sold online is unverified “research” peptide carrying the highest sourcing risk in this category. See Regulatory & Legal Status and Evidence Grading Explained.
- Shared class profile. Both are once-weekly subcutaneous incretin-based agents with dose-dependent GI side effects (nausea, diarrhea, vomiting, constipation) that are worst during escalation, and both rely on slow titration.
Which Is Right For Whom
- Anyone seeking an actual treatment today should be looking at tirzepatide (or another approved agent) under a clinician — it is prescribable, quality-assured, and has an established safety profile.
- Retatrutide is not a current treatment option outside an authorized clinical trial. Its standout efficacy is real in the data but does not change the fact that it is unapproved, of unestablished long-term safety, and unavailable as a legitimate medicine.
- For those tracking the field, retatrutide represents the leading next-generation candidate; its triple-agonist mechanism and Phase 3 numbers are the reason it is closely watched. Lilly has signaled a regulatory submission anticipated in late 2026/early 2027, so it is not expected to be a marketed medicine in the near term. Approval status and final safety data should be confirmed before any practical conclusions.
- Both are decisions that belong with a qualified clinician; neither is a “cycle” compound. See Fat Loss and Metabolic & GLP-1 for class context.
Not medical advice — See Disclaimer.
References
- Jastreboff A.M. et al. (2022). “Tirzepatide Once Weekly for the Treatment of Obesity” (SURMOUNT-1). New England Journal of Medicine.
- Jastreboff A.M. et al. (2023). “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine — −24.2% at 48 weeks, 12 mg.
- Eli Lilly and Company (2026). TRIUMPH-1 Phase 3 topline results — up to −28.3% at 80 weeks; ~−30.3% at 104 weeks (12 mg pathway, BMI ≥35 extension).
- Rosenstock J. et al. (2023). “Retatrutide in patients with type 2 diabetes: a Phase 2 trial.” The Lancet.
- Frías J.P. et al. (2021). “Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes” (SURPASS-2). New England Journal of Medicine.
← Stacks · Home Educational information only — not medical advice. See Disclaimer.